Skip to content
SetPoint Medical employees volunteer at Hope Gardens
SetPoint Medical employees volunteer at Hope Gardens

Valencia, CA – February 15, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing an implantable bioelectronic medicine therapy for chronic inflammatory diseases, is proud to share the news that 25 SetPoint employees spent the day on Wednesday, February 14 volunteering at Hope Gardens Family Center in Los Angeles.

The facility, run by the Union Rescue Mission, provides transitional housing and programs to help homeless women and children move toward independence and includes services ranging from financial and job training to medical and dental care.

SetPoint employees dedicated their day to multiple projects around the Hope Gardens grounds, including clearing brush, sorting donations, cleaning the facility and completing light construction projects. The volunteer day was part of SetPoint’s Helping Hands outreach program, established to coordinate the company’s support for important community causes.

Brenda Biggers and Dang H. Dang working at Hope Gardens
Brenda Biggers and Dang H. Dang with SetPoint Medical working at Hope Gardens

“We’re proud that our employees are giving back to the community by donating their time and skills,” said Anthony Arnold, Chief Executive Officer of SetPoint Medical. “Hope Gardens provides a wide range of services for women and children in need in our area, and we are happy to support their important work.”

About SetPoint Medical

SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative treatment for rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy.

SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific. For more information, visit

#  #  #

Download Press Release